PharmaVOICE - The RWE Evolution

With so much attention being focused on real-world evidence (RWE) and real-world data (RWD), it would be easy to assume that this critical area of drug development is revolutionary. But, in fact, RWE has been around for decades and what the industry is currently experiencing is an evolution of processes founded in solid science and good clinical study practices to support regulatory, payer, and physician stakeholder decisions. That’s not to say there haven’t been some revolutionary forces at play to put patients at the heart of the RWE and RWD movement.


Open PDF

Return to Insights Center

Related Insights

Whitepaper

Combining data tokenization and real-world patient insights to bridge the gap for a more diverse and complete dataset

Apr 2, 2024

Blog

Deriving meaningful insights from real-world data for diverse Alzheimer’s research studies

Mar 19, 2024

Blog

Removing barriers through pragmatic clinical trials

Oct 12, 2023

Blog

Studying rare cancer patient populations using integrated genomic and real-world data

Aug 30, 2023

Blog

A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Webinar

Adaptive strategies for more efficient, data-rich and patient-friendly trials

May 28, 2023

Video

The science and practice of ethnobridging

May 17, 2023

Playbook

Are you using real-world evidence?

Feb 1, 2023

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021